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Background: A deficiency in the counter-regulatory mechanisms of interleukin 1 (IL1) may play a significant role in
endometriosis pathogenesis and associated chronic inflammation. The aim of this study was to investigate peripheral
blood levels of soluble IL1 receptor accessory protein (sIL1RAP), a potent natural inhibitor of IL1, in women with and
without endometriosis.
Methods: Peripheral blood samples were collected from women with endometriosis (n = 47) consulting for infertility,
pelvic pain or tubal ligation, in whom the disease was diagnosed at laparoscopy. Control healthy women (n = 27) were
requesting tubal ligation or reanastomosis and had no visible evidence of endometriosis at laparoscopy. sIL1RAP levels
were determined by ELISA, whereas estradiol (E2) and progesterone (P4) levels were determined by competitive
immunoassays.
Results: sIL1RAP levels were significantly decreased in women with early endometriosis stages compared to controls
(p < 0.05) and markedly during the proliferative phase of the menstrual cycle (p < 0.001). Actually, while sIL1RAP were
significantly increased in the proliferative compared to the secretory phase in normal women (p < 0.0001) and peaked
at the end of this phase, sIL1RAP remained consistently low and showed non-significant variations throughout
the menstrual cycle in women with endometriosis.
Conclusions: Lower circulating levels of sIL1RAP points to a significant impairment in the counter-regulatory
mechanisms of IL1, which in view of the cytokine’s potent inflammatory and growth-promoting properties may
play a significant role in the pathophysiology of endometriosis.
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Endometriosis is one of the most frequent gynaecological
diseases in reproductive age women. A one in ten woman
suffers from endometriosis in North America. Defined as
an ectopic growth of endometrial tissue, endometriosis is
frequently associated pelvic pain and infertility (30-40%)
[1] and a chronic pelvic inflammation [2].
Cumulative evidence clearly points to a significant role
for immune factors in endometriosis development. Inflam-
mation is a major hallmark of endometriosis, but the
underlying mechanisms are not clearly elucidated. Local
immune surveillance appears to be deficient in women* Correspondence: ali.akoum@crsfa.ulaval.ca
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unless otherwise stated.with endometriosis and immune cells seem to paradox-
ically favor ectopic endometrial cell growth via different
mechanisms that include secretion of inflammatory,
angiogenic and growth mediators such as monocyte
chemotactic protein 1 (MCP1), macrophage migration
inhibitory factor (MIF), interleukin 1 (IL1), IL8, and
vascular endothelial cell growth factor (VEGF) [3]. These
contribute to endometriosis-associated chronic peritoneal
inflammation, but also to endometrial cell survival, attach-
ment to the peritoneal tissue, invasion, proliferation and
activation of the host angiogenic responses [3]. Endome-
triotic implants are likely to stimulate leukocyte recruit-
ment and activation, and endometrial dysfunctions may
contribute to the activation of peritoneal immune cellsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics of patients at the time of
laparoscopy
No. of patients Age (yr) (mean ± SD)
Controls 27 36.2 ± 5.6
Endometriosis 47 31.9 ± 4.3
Stages I-II 36 32.1 ± 4.6
Stages III-IV 11 31.0 ± 2.8
Fertile 11 33.0 ± 5.2
Infertile 36 31.7 ± 4.0
Without pain 33 31.8 ± 4.4
With pain 14 31.9 ± 3.8
Proliferative phase
Controls 14 34.3 ± 6.4
Endometriosis 19 30.9 ± 4.5
Secretory phase
Controls 13 37.8 ± 4.7
Endometriosis 28 32.5 ± 4.0
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reflux of menstrual debris into the peritoneal cavity [3-7].
Nevertheless, alterations in immune functions observed
in patients having endometriosis are not restricted to
the peritoneal cavity, where the disease is frequently
found. Systemic alterations including increased levels of
cytokines [8], reduced cytotoxic effects of lymphocytes
on autologous endometrial cells and increased activation
of peripheral blood monocytes [9,10] were reported. These
cells also appeared to stimulate endometrial cell growth
in vitro [9,11].
Our and other previous studies found reduced concen-
trations of sIL1R2 in the peripheral blood of women with
endometriosis [12,13]. This decoy receptor is a potent
natural inhibitor of IL1 [14], which suggests an impairment
in IL1 surveillance and counter-regulatory mechanisms
in women with endometriosis at the systemic level. IL1
activates cells via its receptor type 1 (IL1R1) and the in-
volvement of membrane-bound receptor accessory protein
(mIL1RAP) [15]. However, a soluble form of IL1RAP
(sIL1RAP), which results from alternative splicing rather
than form proteolytic cleavage of the membrane-bound
receptor extracellular domain, has been described. sIL1-
RAP was detected in human serum and appeared to play
an important role in the counter-regulation of IL1 effects
by increasing the affinity of IL1 binding to sIL1R2 [16].
Our subsequent studies showed that sIL1RAP levels
were significantly decreased in the endometrium and
peritoneal fluid of women with endometriosis [17,18].
The aim of this study was then to evaluate sIL1RAP
concentrations in sera of endometriosis patients and
investigate the influence of endometriosis stage and




Women were recruited into the study after providing
an informed consent for a research protocol approved
by the CHU de Quebec Ethics Committee on Human
Research. Subjects with endometriosis (n = 47; mean
age, 31.9 ± 4.3 years) were consulting for pelvic pain,
dysmenorrhea, dyspareunia and/or infertility or were
asymptomatic and requesting tubal ligation. Endometriosis
was diagnosed at laparoscopy/laparotomy before any
medical or surgical intervention and staged according
to the revised classification of the American Fertility
Society (rAFS) [19]. Women with endometriosis who
were included in this study displayed no other pelvic
pathology and had not taken any anti-inflammatory or
hormone medication at least three months before laparos-
copy. Control subjects (n = 27; mean age, 36.2 ± 5.6 years)
were fertile women undergoing laparoscopy for tubal
ligation or reanastomosis in whom neither laparoscopicevidence of endometriosis nor other pathologies (leio-
myoma, uterine fibroids or pelvic infection) are found.
These women were fertile, had regular menstrual cycles,
and had not taken anti-inflammatory or hormone medica-
tion at least three months before laparoscopy. The men-
strual cycle phase (proliferative or secretory) for all patients
was determined based on cycle history, serum oestradiol
(E2) and progesterone (P4) levels and histological examin-
ation of endometrial biopsies when available according to
the criteria of Noyes et al. [20]. The main clinical character-
istics used in this study are summarized in Table 1.
Collection and processing of blood samples
Blood was collected in sterile tubes containing ethylene-
diaminetetracetic acid (EDTA), immediately centrifuged
at 2,000 g for 10 minutes at 4°C, and the serum aliquoted
and stored at −80°C until assay. For hormonal assays,
blood was collected in redtop tubes and sent to the bio-
chemistry laboratory for current steroid determination.
IL1RAP enzyme-linked immunosorbent assay (ELISA)
Soluble IL1RAP concentrations in sera were measured by
an ELISA procedure designed in our laboratory. Ninety-
six-well microtiter plates (Corning Incorporated Life
Sciences, Lowell, MA, USA) were coated overnight at
4°C with anti-hIL1RAP polyclonal antibody [0.71 μg/
mL in phosphate buffered saline (PBS)] (R&D Systems,
Minneapolis, MN, USA). Wells were washed with PBS
containing 0.1% Tween-20 (PBS-Tween) and incubated
for 1 h at 37°C with PBS containing 3% bovine serum
albumin (BSA) (PBS-BSA). Samples and shIL1RAP (R&D
Systems) were diluted in PBS-BSA, added to wells and
incubated successively with biotinylated anti-shIL1RAP
Figure 1 sIL1RAP concentrations in blood samples of patients
without or with different endometriosis stages. A, normal
controls (NC) and women with endometriosis (E); B, normal controls
(NC) and women with endometriosis distributed according to the
stage of the disease (EI/II and EIII/IV). The horizontal lines represent
the mean for each set of data. *p < 0.05 as compared to NC.
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Systems) for 1 h at 37°C, peroxidase-labeled streptavidin
HRP-peroxidase (1 μg/mL in PBS-BSA) (Jackson Immu-
noResearch Laboratories, West Grove, PA) for 45 min at
37°C and finally with TMB (3,3′, 5,5′,-tetramethylbenzi-
dine) (Bio-Rad Laboratories Ltd, Mississauga, Ontario,
Canada) as peroxidase substrate for 5 min at room
temperature. The reaction was then stopped with 2 N
sulphuric acid (H2SO4) and the optical density (OD)
determined at 450 nm. sIL1RAP concentrations were
calculated by interpolation from standard curves using
shIL1RAP (R&D Systems) at concentrations varying be-
tween 2 and 128 ng/mL and showing a sensitivity limit of
approximately 0.4 ng/mL. Measurements were performed
in duplicate. All samples were assessed at the same time
to prevent any possible changes due to freezing and thaw-
ing. The inter- and intra-assay coefficients of variation for
the sIL1RAP assay were 5.8% and 8.0%, respectively.
E2 and P4 assays
Serum E2 and P4 were measured by competitive immu-
noassays based on antibody-coated tubes (commercial
kits, Coat-A-Count; Diagnostic Products Corp., Los Angeles,
CA). The intra-assay coefficients of variation measured at
low, medium, and high levels of the standard curves were
between 1.8% and 8.0% for all the immunoassays. The
inter-assay coefficients of variation were less than 8.0% for
E2 and 10% for P4.
Statistical analysis
sIL1RAP concentrations followed a Gaussian distribution
and were statistically analysed using one-way analysis of
variance (ANOVA) and the Bonferroni’s test for post hoc
for multiple comparisons. Comparison of 2 groups was
performed using the unpaired t test (Prism 3.0, GraphPad
Software, San Diego, CA, USA). Differences were consid-
ered as statistically significant at p < 0.05. The statistical
power was calculated online using a Statistical Power




sIL1RAP was detected in the peripheral blood and the
distribution of its concentrations in normal controls and
women with endometriosis are presented in Figure 1.
sIL1RAP levels were slightly decreased in women with
endometriosis, but this decrease did not reach the level
of statistical significance (p = 0.08) (Figure 1A). A signifi-
cant decrease was nevertheless observed in women with
endometriosis stages I-II compared to normal controls
(p < 0.05), but not in the advanced stages III-IV of the
disease (Figure 1B). Data analysis taking into account
the fertility status of women with endometriosis or thepresence and absence of pelvic pain showed no statistically
significant differences with normal controls (Figure 2A
and B).
Analysis of sIL1RAP levels according to the menstrual
cycle phase first showed a significant diminution during
the secretory phase compared to the proliferative phase
in normal controls (p < 0.0001) (statistical power, 97.5%)
(Figure 3A). In women with endometriosis, no significant
difference between the proliferative and the secretory
phases was noted. As compared to normal controls how-
ever, patients with endometriosis showed a statistically
significant diminution of sIL1RAP levels in the prolifer-
ative phase (p < 0.001), but not in the secretory phase
(statistical power, 100% and 95%, respectively) (Figure 3A).
Further distribution of sIL1RAP values along the men-
strual cycle showed a peak, which, in normal women, was
reached at the end of the proliferation phase. In women
with endometriosis, however, the amplitude of such a
peak was significantly lower (p < 0.01) compared to nor-
mal controls (statistical power, 80%), and no significant
cycle-dependent changes could be observed (Figure 3B).
Since these results suggest a hormonal regulation of
Figure 2 sIL1RAP concentrations in blood samples of patients
without or with endometriosis distributed according to the
fertility status or pelvic pain. A, normal controls (NC) and women
with endometriosis distributed according to the fertility status (EF,
endometriosis fertile and EI, endometriosis infertile); B, normal controls
(NC) and women with endometriosis distributed according to the
absence or presence of pelvic pain (EWOP, endometriosis without pain
and EWP, endometriosis with pain). The horizontal lines represent the
mean for each set of data.
Figure 3 sIL1RAP concentrations in blood samples of patients
without and with endometriosis distributed according to the
menstrual cycle phase. A, sIL1RAP concentration in normal
controls and women with endometriosis in the proliferative (NP and
EP, respectively) and the secretory (NS and ES, respectively) phases
of the cycle. B, Cyclic variations of sIL1RAP concentrations in women
with and without endometriosis. EMP, early-mid proliferative; LP, late
proliferative; EMS, early-mid secretory; LS, late secretory. The horizontal
lines represent the mean for each set of data; ***p < 0.001 as compared
to NP; ++p < 0.01 as compared to NC.








Controls 14 300.8 ± 65.4 5.8 ± 2.4
Endometriosis 19 268.3 ± 39.6 2.3 ± 0.3
Luteal phase
Controls 13 375.7 ± 74.1 17.6 ± 4.1
Endometriosis 28 485.1 ± 57.6 26. 2 ± 3.8
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tions in the same serum samples. Data displayed in
Table 2 showed no statistically significant differences in
E2 or P4 levels between normal controls and women
with endometriosis in the proliferative or the secretory
phase of the menstrual cycle. Furthermore, no signifi-
cant correlation between sIL1RAP levels and those of
E2 or P4 was found in women with endometriosis or
normal controls (data not shown).
Discussion
In the present study, we found that sIL1RAP levels were
not significantly altered in the peripheral blood of women
with endometriosis; only a slight diminution was observed
compared to normal women. Our data did not point to
any noticeable relationship with endometriosis-related
infertility or pelvic pain, as sIL1RAP levels were compar-
able in fertile and infertile women with endometriosis
and in those who have or not pelvic pain. However,data analysis according to endometriosis stage revealed
a statistically significant decrease in the earliest stages
of the disease. The number of EIII/IV patients included
in this study was too small to draw a definite conclusion
on sIL1RAP relationship with advanced endometriosis
stages. Nevertheless, our findings are consistent with
the available literature showing that endometriosis is
biochemically more active in the early stages. Actually,
it is quite believed that endometriotic lesion types rep-
resent distinctive steps in the evolutionary process of
the disease and that initial and highly active, vascular-
ized and inflammatory red lesions display an increased
expression of pro-inflammatory, angiogenic and tissue
remodelling factors such as nuclear factor (NF)-kB,
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and prostaglandins (PGs) [21-25].
Analysis of sIL1RAP concentrations according to the
menstrual cycle further revealed a significant decrease
during the proliferative phase in women with endometri-
osis compared to controls, and precisely at the end of
this phase; a phenomenon that was not observed during
the secretory phase. Actually, sIL1RAP levels were sig-
nificantly lower in the proliferative than in the secretory
phase in normal healthy controls, whereas in women with
endometriosis they showed no significant cycle-dependent
variations and remained low throughout the menstrual
cycle. Analysis of E2 and P4 levels in the peripheral blood
sera of the same women did not reveal any significant
endometriosis-related changes, nor did it identify a signifi-
cant correlation with sIL1RAP levels, which rules out their
involvement in the regulation of sIL1RAP levels in the
peripheral blood. The decrease in circulating sIL1RAP
levels remains unexplained and so are the source(s) of
sIL1RAP secretion. sIL1RAP was detected in human
serum [16], but it is unknown whether immune blood
cells, the predominant cell population in the peripheral
blood, could be responsible for sIL1RAP production. Fur-
thermore, immune cell dysfunctions have been described
in sera of patients with endometriosis and could explain
this phenomenon [3,7-9,26,27]. However, we cannot com-
pletely rule out an eventual endometrial origin since our
previous study showed that human endometrium is cap-
able of producing sIL1RAP [18]. Considering that the
endometrium is a highly vascularized tissue, a decrease in
the secretion of endometrial sIL1R3 could, at least partly,
explain our current results. It would however be interest-
ing to evaluate the production of sIL1R3 in immune blood
cells of women with and without endometriosis.
Our findings may have a significant relevance for endo-
metriosis pathophysiology. Actually, sIL1RAP is a major
specific inhibitor of IL1. Unlike the constitutive membrane-
bound form of IL1RAP, which is necessary for IL1-mediatd
cell activation via the functional activating IL1R1, sIL1RAP
potentiates IL1 affinity for the decoy inhibitory IL1R2 and
plays thereby a significant role in the down-regulation of
the cytokine’s pro-inflammatory effects [14,16,28]. IL1 A
and B forms were detected in the peripheral blood, but
their increased concentrations in women with endometri-
osis reported by some studies were not corroborated by
other studies [12,13,29]. However, the significant decline in
serum sIL1RAP levels in endometriosis stages I-II shown
in the current study together with the reduced concentra-
tion of sIL1R2 shown by our and other previous studies,
particularly in stages I-II as well [12,13], clearly point to a
significant deficiency in the specific regulatory mechanisms
of IL1 at the systemic level in the earliest stages of the dis-
ease. Endometriosis-associated immune and inflammatory
changes were mainly located within the peritoneal cavityof endometriosis patients, where the disease frequently
develops, and especially within endometriotic lesions
where immune cell infiltration and endometriotic cell
activation and expression of inflammatory, tissue re-
modelling and growth factors were reported [2,8,30-32].
However, although relatively less obvious, intrauterine
and even systemic immune-inflammatory changes, such
as increased activation of monocytes and secretion of
pro-inflammatory cytokines, have also been observed in
women with endometriosis [3,7-9,26,27].
sIL1RAP was found to be down-regulated in eutopic
endometrial tissue of women with endometriosis and a
significant decline in the concentration of this molecule
was found in the peritoneal fluid as well [33]. This, con-
sidering the pro-inflammatory, angiogenic and growth
promoting properties of IL1 [14,34-36] and its increased
production in endometriotic tissue [33], suggests that a
combination of local and systemic deficiency in sIL1RAP
may lead to an increased endometriotic cell activation
by IL1 and contribute to the promotion of the ectopic
growth and development of these cells. It is noteworthy
that because of its potent anti-inflammatory properties,
IL1RAcP has been shown to ameliorate collagen-induced
arthritis in vivo using a collagen-induced-arthritis mouse
model [28,37]. In fact, its ability to interact with IL1 seems
to play a substantial role in the regulation of inflammation
since it has been approved for therapeutic use as an IL1
trap fusion protein [38]. Therefore, it would be of interest
to evaluate sIL1RAcP efficacy as a potential treatment of
endometriosis using mouse models.
Conclusions
Our study showed for the first time a cycle phase de-
pendency for sIL1RAP levels in the peripheral blood of
normal healthy women, which peak in the proliferative
phase of the menstrual cycle, but instead showed non-
significant variations throughout the menstrual of women
with endometriosis. Lower circulating levels of sIL1RAP
may, in combination a deficiency in sIL1RAP expression
in eutopic endometrium and a reduction in its peritoneal
fluid concentrations, be relevant to endometriosis patho-
physiology as it points to a significant lack in the counter-
regulatory mechanisms of IL1-mediated inflammation,
tissue remodelling and cell growth. The source(s) of sIL1-
RAP deficiency in the peripheral blood and the involved
regulatory pathways need to be investigated.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NM performed the experiments and wrote the first version of the
manuscript. MA contributed to statistical analysis and helped in the analysis
of the results and writing of the manuscript. AA set up design, supervised
experiments and data analysis and reviewed, corrected and finalized the
manuscript. All authors have read and approved the final manuscript.
Michaud et al. Reproductive Biology and Endocrinology 2014, 12:51 Page 6 of 6
http://www.rbej.com/content/12/1/51Acknowledgements
The authors wish to thank Drs Sylvie Bazin, Pierre Blanchet, Marleen Daris,
Karine Girard, Julie Guillemette, Mathieu Leboeuf, Madeleine Lemyre, Isabelle
Lévesque, Jacques Mailloux and Marie-Christine Roy for patient evaluation
and providing peripheral blood samples and Nathalie Bourcier, Amélie
Bourdiec, Madeleine Desaulniers for technical assistance. This study was
supported by grant MOP-93716 to Ali Akoum from the Canadian Institutes
for Health Research. A.A. is a “Chercheur-Boursier National” of the “Fonds de
la Recherche du Québec-Santé (FRQ-S)”.
Received: 4 April 2014 Accepted: 10 June 2014
Published: 16 June 2014References
1. Giudice LC: Clinical practice. Endometriosis N Engl J Med 2010, 362:2389–2398.
2. Lousse JC, Langendonckt AV, Defrere S, Ramos RG, Colette S, Donnez J:
Peritoneal endometriosis is an inflammatory disease. Front Biosci 2012,
4:23–40.
3. Khoufache K, Michaud N, Harir N, Kibangou Bondza P, Akoum A: Anomalies
in the inflammatory response in endometriosis and possible
consequences: a review. Minerva Endocrinol 2012, 37:75–92.
4. Akoum A, Lemay A, Brunet C, Hebert J: Cytokine-induced secretion of
monocyte chemotactic protein-1 by human endometriotic cells in
culture: the groupe d’investigation en gynecologie. Am J Obstet Gynecol
1995, 172:594–600.
5. Tseng JF, Ryan IP, Milam TD, Murai JT, Schriock ED, Landers DV, Taylor RN:
Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic
endometrial stromal cells from women with endometriosis. J Clin
Endocrinol Metab 1996, 81:1118–1122.
6. Halme J, Becker S, Wing R: Accentuated cyclic activation of peritoneal
macrophages in patients with endometriosis. Am J Obstet Gynecol 1984,
148:85–90.
7. Kobayashi H, Uekuri C, Shigetomi H: Towards an understanding of the
molecular mechanism of endometriosis: unbalancing epithelial-stromal
genetic conflict. Gynecol Endocrinol 2014, 30:7–15.
8. Borrelli GM, Abrao MS, Mechsner S: Can chemokines be used as
biomarkers for endometriosis? A systematic review. Hum Reprod 2014,
29:253–266.
9. Braun DP, Gebel H, House R, Rana N, Dmowski NP: Spontaneous and
induced synthesis of cytokines by peripheral blood monocytes in
patients with endometriosis. Fertil Steril 1996, 65:1125–1129.
10. Dmowski WP, Steele RW, Baker GF: Deficient cellular immunity in
endometriosis. Am J Obstet Gynecol 1981, 141:377–383.
11. Braun DP, Muriana A, Gebel H, Rotman C, Rana N, Dmowski WP: Monocyte-
mediated enhancement of endometrial cell proliferation in women with
endometriosis. Fertil Steril 1994, 61:78–84.
12. Kharfi A, Akoum A: Soluble interleukin-1 receptor type II blocks monocyte
chemotactic protein-1 secretion by U937 cells in response to peripheral
blood serum of women with endometriosis. Fertil Steril 2002, 78:836–842.
13. Kondera-Anasz Z, Sikora J, Mielczarek-Palacz A, Jonca M: Concentrations of
interleukin (IL)-1alpha, IL-1 soluble receptor type II (IL-1 sRII) and IL-1 re-
ceptor antagonist (IL-1 Ra) in the peritoneal fluid and serum of infertile
women with endometriosis. Eur J Obstet Gynecol Reprod Biol 2005,
123:198–203.
14. Sims JE, Smith DE: The IL-1 family: regulators of immunity. Nat Rev
Immunol 2010, 10:89–102.
15. Gabay C, Lamacchia C, Palmer G: IL-1 pathways in inflammation and
human diseases. Nat Rev Rheumatol 2010, 6:232–241.
16. Smith DE, Hanna R, Della F, Moore H, Chen H, Farese AM, MacVittie TJ, Virca
GD, Sims JE: The soluble form of IL-1 receptor accessory protein en-
hances the ability of soluble type II IL-1 receptor to inhibit IL-1 action.
Immunity 2003, 18:87–96.
17. Michaud N, Al-Akoum M, Gagnon G, Girard K, Blanchet P, Rousseau JA,
Akoum A: Decreased concentrations of soluble interleukin-1 receptor
accessory protein levels in the peritoneal fluid of women with
endometriosis. J Reprod Immunol 2011, 92:68–73.
18. Guay S, Michaud N, Bourcier N, Leboeuf M, Lemyre M, Mailloux J, Akoum A:
Distinct expression of the soluble and the membrane-bound forms of
interleukin-1 receptor accessory protein in the endometrium of women
with endometriosis. Fertil Steril 2011, 95:1284–1290.19. Revised American society for reproductive medicine classification of
endometriosis: 1996. Fertil Steril 1997, 67:817–821.
20. Noyes RW, Hertig AT, Rock J: Dating the endometrial biopsy. Am J Obstet
Gynecol 1975, 122:262–263.
21. Vernon MW, Beard JS, Graves K, Wilson EA: Classification of endometriotic
implants by morphologic appearance and capacity to synthesize
prostaglandin F. Fertil Steril 1986, 46:801–806.
22. Kokorine I, Nisolle M, Donnez J, Eeckhout Y, Courtoy PJ, Marbaix E: Expression
of interstitial collagenase (matrix metalloproteinase-1) is related to the
activity of human endometriotic lesions. Fertil Steril 1997, 68:246–251.
23. Kats R, Metz CN, Akoum A: Macrophage migration inhibitory factor is
markedly expressed in active and early-stage endometriotic lesions.
J Clin Endocrinol Metab 2002, 87:883–889.
24. Lawson C, Al-Akoum M, Maheux R, Akoum A: Increased expression of
interleukin-1 receptor type 1 in active endometriotic lesions.
Reproduction 2007, 133:265–274.
25. Gonzalez-Ramos R, Van Langendonckt A, Defrere S, Lousse JC, Colette S,
Devoto L, Donnez J: Involvement of the nuclear factor-kappaB pathway
in the pathogenesis of endometriosis. Fertil Steril 2010, 94:1985–1994.
26. Kyama CM, Overbergh L, Debrock S, Valckx D, Vander Perre S, Meuleman C,
Mihalyi A, Mwenda JM, Mathieu C, D’Hooghe TM: Increased peritoneal and
endometrial gene expression of biologically relevant cytokines and
growth factors during the menstrual phase in women with
endometriosis. Fertil Steril 2006, 85:1667–1675.
27. Kyama CM, Overbergh L, Mihalyi A, Meuleman C, Mwenda JM, Mathieu C,
D’Hooghe TM: Endometrial and peritoneal expression of aromatase,
cytokines, and adhesion factors in women with endometriosis. Fertil Steril
2008, 89:301–310.
28. Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin
MU, van den Berg WB, van de Loo FA: Soluble interleukin-1 receptor
accessory protein ameliorates collagen-induced arthritis by a different
mode of action from that of interleukin-1 receptor antagonist. Arthritis
Rheum 2005, 52:2202–2211.
29. Koumantakis E, Matalliotakis I, Neonaki M, Froudarakis G, Georgoulias V:
Soluble serum interleukin-2 receptor, interleukin-6 and interleukin-1a in
patients with endometriosis and in controls. Arch Gynecol Obstet 1994,
255:107–112.
30. Kyama CM, Mihalyi A, Simsa P, Falconer H, Fulop V, Mwenda JM, Peeraer K,
Tomassetti C, Meuleman C, D’Hooghe TM: Role of cytokines in the
endometrial-peritoneal cross-talk and development of endometriosis.
Front Biosci (Elite Ed) 2009, 1:444–454.
31. Berbic M, Fraser IS: Regulatory T cells and other leukocytes in the
pathogenesis of endometriosis. J Reprod Immunol 2011, 88:149–155.
32. Defrere S, Gonzalez-Ramos R, Lousse JC, Colette S, Donnez O, Donnez J,
Van Langendonckt A: Insights into iron and nuclear factor-kappa B
(NF-kappaB) involvement in chronic inflammatory processes in peritoneal
endometriosis. Histol Histopathol 2011, 26:1083–1092.
33. Bergqvist A, Bruse C, Carlberg M, Carlstrom K: Interleukin 1beta,
interleukin-6, and tumor necrosis factor-alpha in endometriotic tissue
and in endometrium. Fertil Steril 2001, 75:489–495.
34. Lebovic DI, Bentzien F, Chao VA, Garrett EN, Meng YG, Taylor RN: Induction
of an angiogenic phenotype in endometriotic stromal cell cultures by
interleukin-1beta. Mol Hum Reprod 2000, 6:269–275.
35. Akoum A, Jolicoeur C, Boucher A: Estradiol amplifies interleukin-1-induced
monocyte chemotactic protein-1 expression by ectopic endometrial cells
of women with endometriosis. J Clin Endocrinol Metab 2000, 85:896–904.
36. Akoum A, Lawson C, McColl S, Villeneuve M: Ectopic endometrial cells
express high concentrations of interleukin (IL)-8 in vivo regardless of the
menstrual cycle phase and respond to oestradiol by up-regulating IL-1-
induced IL-8 expression in vitro. Mol Hum Reprod 2001, 7:859–866.
37. Smeets RL, van de Loo FA, Joosten LA, Arntz OJ, Bennink MB, Loesberg WA,
Dmitriev IP, Curiel DT, Martin MU, van den Berg WB: Effectiveness of the soluble
form of the interleukin-1 receptor accessory protein as an inhibitor of
interleukin-1 in collagen-induced arthritis. Arthritis Rheum 2003, 48:2949–2958.
38. Ratner M: IL-1 trap go-ahead. Nat Biotechnol 2008, 26:485.
doi:10.1186/1477-7827-12-51
Cite this article as: Michaud et al.: Blood soluble interleukin 1 receptor
accessory protein levels are consistently low throughout the menstrual
cycle of women with endometriosis. Reproductive Biology and Endocrinology
2014 12:51.
